A study carried out in the province of Santa Fe showed that the level of antibodies tripled in those of legal age who received the first dose of Suptnik V vaccines and completed their regimen with Moderna.
The work was carried out with professionals from the Ministry of Health of Santa Fe, the Center for Technology in Public Health (CTSP) of the Faculty of Biochemical and Pharmaceutical Sciences of the National University of Rosario (UNR) and the Provincial Hospital of Centenario.
The researcher Ana Laura Cavatorta, responsible for the study, explained that the work was carried out between August and October 2021 in the vaccination center of the Ex Rural de Rosario with 303 volunteers who completed their heterologous immunization schedule, with a first dose of Sputnik V and a second of Moderna.
“Of all the volunteers, 65% were women and 35% men, among whom 67% were older than 60 years,” said Cavatorta, professor in Virology and researcher at Conicet.
Cavatorta explained that in those over 60 who received the first dose of Sputnik V (adenovirus technology) and completed the scheme with one carried out using messenger RNA such as Moderna “the response was greater than in homologous schemes, even tripling the value of the antibodies “.
“This change in technologies at the level of the immune system of people returns to the more immunogenic scheme. Two stimuli with two different vaccines are recognized as very foreign to the body, and the response is much more effective, something that we verify locally, and which corresponds to studies worldwide “Cavatorta added.
The researcher said that “in adults over 60 the first dose of Sputnik had already generated a significant but medium impact, in terms of the antibody titer or concentration.”
“However, after a second dose of Moderna was placed, the value of these antibodies tripled. In those under 60 there were no important changes. The response was as expected, but not as in the previous group,” he completed .
–
